US EditionNovo Nordisk's Wegovy weight loss drug sales soar 67% in second quarter
Summary by CNBC
2 Articles
2 Articles
Sales of Novo Nordisk’s diabetes drugs including Ozempic slow sharply
Fierce competition and threat of Trump tariffs lead to Danish company cutting costsSales of Novo Nordisk’s injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus.The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe’s most valuable company, has lost $95bn (£71.…
Coverage Details
Total News Sources2
Leaning Left1Leaning Right0Center1Last UpdatedBias Distribution50% Left, 50% Center
Bias Distribution
- 50% of the sources lean Left, 50% of the sources are Center
50% Center
L 50%
C 50%
Factuality
To view factuality data please Upgrade to Premium
